Answer
Fatigue/asthenic conditions occurred in 13.7% of patients receiving darolutamide in the pooled ARAMIS and ARANOTE analysis and were the most common adverse reactions.
Sources for this answer
- NUBEQA 300 mg film coated tabletsBayer plc · emc · SmPC §4.8 Undesirable effects · Version 10Document updated
Sources checked